For decades, gluten-free dieting (GFD) has been accepted as the only therapeutic approach to coeliac disease (CD) and, more recently, for non-coeliac gluten sensitivity (NCGS), a term to refer to the so-called gluten-related disorders (GRD) [1] .
Further evidence, recently accepted, shows that in spite of improvements in food formulation over the last few years, GF foods still present with a reduced nutritional profile when compared with gluten-containing products, with higher lipid and trans-fat content; lower level of proteins; and lower degree of fortification with micronutrients, especially Ca, Fe, Mg, and Zn [14] . Similarly, Wiech et al. have shown that CD children adhering to GFD for a year showed a higher increase in weight and body mass index (BMI) when compared with healthy controls, suggesting a tendency towards metabolic syndrome [15] . However, there is growing evidence supporting the protective effect of GFD on bone metabolism [16] and the possible prevention of diabetes through GFD [17] .
In preparing this Special Issue, GFD and fermentable oligo/di/monosaccharides and polyols (FODMAP) as dietary therapies in individuals with IBS was an issue that the Editors found to be important [18] .
In a study evaluating the intake of foods containing fermentable oligo/di/monosaccharides and polyols (FODMAP) in CD patients, Roncoroni et al. confirmed that the prevalence of IBS-type symptoms among CD patients is higher than in the general population. Moreover, they demonstrated that CD patients consume a diet high on FODMAP, which is a factor that possibly induces gastrointestinal symptoms in treated CD patients [19, 20] . Moreover, in the first RCT DB intervention controlled study, the same researchers showed that CD patients on GFD, but with persisting functional gastrointestinal symptoms, had a positive response to a diet low on FODMAP. Thus, GFD associated with a low-FODMAP content is beneficial, as a support therapy, for a group of CD patients with persistent gastrointestinal symptoms [21] .
A number of questions still remain unanswered; namely, the modifications by GFD of the gut microbiota in different populations [22, 23] ; the effects of gluten intake on both gastric and gallbladder motility [24] ; and the persistent motor disorders in CD patients, despite GFD, which can be explained by low-grade mucosal inflammation [25] .
Several open issues regarding GFD also remain, such as, most importantly, the ingestion threshold for the amount of gluten considered tolerable has not been defined yet. Furthermore, the appropriateness of a lifelong indication to GFD, particularly for patients with sub-clinical and potential CD (i.e., not confirmed by histology), is still a matter of debate [26] , especially on consideration of the impact on patients' quality of life posed by a restrictive gluten-free diet [27] . Finally, in a study on the immunogenic potential of α-gliadins in Triticale, Ruiz-Carnicer et al. demonstrated that by substituting a natural amino acid to the most immunogenic fraction of gluten (DQ2.5-glia-a 1, DQ2.5-glia-a2, and DQ2.5-glia-a3), the toxicity of three T-cell epitopes was eliminated, while the technological properties of commercial wheat were maintained [28] . These results may offer the opportunity to generate wheat varieties with a reduced CD immunogenicity not safe for consumption by patients, but that might help to prevent the onset of CD in people that carry genetic risk factors.
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